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. The second is a retrospective audit from colleagues in India assessing the applicability of the Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis prognostic classes for brain metastases in this context [2] . We applaud the continued interest in the optimal treatment of patients with non-small cell lung cancer and brain metastases, but must highlight a number of issues within these publications that cause us concern.
The letter from Bradley et al. [1] concerns a retrospective analysis of a small number of highly selected patients, with only the better performance status patients (World Health Organization 0 and 1; Karnofsky performance score [KPS] 100e70) receiving whole brain radiotherapy (WBRT). Although performance status is a well-known and important prognostic factor, it has never been shown to be a predictor for a response or lack of one to a specific treatment d in this case WBRT [3] . We thus question the use of this sole measure to determine treatment. Any measured difference in survival within this non-randomised highly selected group cannot solely be attributed to the decision to provide or not to provide WBRT, particularly in view of the heterogeneous list of other treatments this patient group received.
In the publication from Mumbai [2] , the main conclusion was that 20 Gy in five fractions is as effective as longer fractionated courses. This fact has already been shown by the multiple RTOG dose-finding trials in the 1970s and 1980s [4, 5] , the Royal College of Radiologists' publication from 1996 [6] and the Cochrane review of 2006 [7] . However, as the Cochrane review points out, there has never been a full randomised controlled trial of supportive care plus or minus WBRT and this information is of utmost importance, particularly in the non-small cell lung cancer group. Within the Mumbai series, poor survival times were again seen: median overall survival was 4.0 months (range 0.5e30.0 months) and emphasised that the central question being addressed by QUARTZ remains as valid as ever.
Similarly, the addition of systemic therapy to WBRT, which occurred in both publications, cannot be claimed to improve survival as those patients receiving this treatment fall within a self-selecting population, with only the fittest patients (and thus those with the better prognoses) receiving treatment. Of the various prognostic factors explored in the publication from Mumbai, recursive partitioning analysis class (II versus III, P value ¼ 0.023), KPS (<70 versus !70, P value ¼ 0.039) and the use of systemic therapy emerged as significant on univariate analysis. The use of systemic therapy in these patients again reflects their performance statusdit cannot be concluded that the use of systemic therapy improved survival from the data presented.
Systemic therapies may have a role to play, but that role must be explored and elucidated in randomised clinical trials. QUARTZ continues to play an important role in establishing the standard of care against which these new modalities should be tested.
A recent release of preliminary data from the first 151 QUARTZ patients (manuscript in preparation) suggests that not using WBRT does not result in obviously shortened survival or decreased quality of life. These data show a 6 month survival rate of <10%, suggesting that no particular group of patients greatly benefits from WBRT. The wide range of baseline characteristics observed in the QUARTZ data (50% of patients entered were of KPS >70; 50% < KPS 70) suggests that there remains widespread uncertainty over how to treat all patients, regardless of performance status. WBRT may be effective in some patients, but at present there is little evidence to allow the identification of those patients. This interim release has been helpful to reassure clinicians and patients partaking in QUARTZ that no harm is seen in either arm from the point of view of the length of survival. To fully answer the questions that pertain to potential benefits from WBRT re survival and patientassessed quality adjusted life years (the primary end point of QUARTZ), we must await completion of this trial to attain the statistical power required.
The view of the QUARTZ TMG is that both publications [1, 2] used cohorts of patients who had received WBRT to support the use of WBRT, but using such data can never produce the justification for this assumption. It may indeed be that all patients benefit from WBRT, but equally the data presented (because of the poor survival) could indicate that it is actually detrimental to all patients. The likelihood is that some subgroups of patients benefit and some do not, but only by performing large randomised trials, and comparing those who received WBRT with a comparable group who did not, can we tease out these differences. Clinical practice must be evidence based, not anecdotal. All patients deserve the best available treatment, and the best way of determining that is within clinical trials. Early QUARTZ data suggest there is considerable uncertainty as to how these patients should be treated, and further investigation is essential. Patients with non-small cell lung cancer and brain metastases who may have received chemotherapy or targeted agents up front remain eligible for QUARTZ. As such, we believe all patients, regardless of performance status, should be considered for QUARTZ, and that the current standard of care for these patients should be inclusion in the trial. 
